Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • AAN 2026

American Academy of Neurology (AAN)
Annual Meeting

 April 18 - 22, 2026

  1. All
  2. MG
  3. NF1-PN
  4. NMOSD

PDF

Concomitant immunosuppressive therapy use with ravulizumab: analysis of the global MG SPOTLIGHT registry

PDF

Efficacy and safety of subcutaneous self-administered gefurulimab in gMG: primary results from the phase 3, randomized, double-blind, placebo controlled PREVAIL trial

PDF

Impact on healthcare resource utilization in early initiators of ravulizumab versus efgartigimod for treatment of generalized myasthenia gravis in the USA

HTML

ME&MG TM digital biomarkers correlate with equivalent MG-ADL and MG-QoL15r sub-items scores

PDF

MG-ADL subdomain score changes with eculizumab or ravulizumab: an analysis of the global MG SPOTLIGHT registry

PDF

Patient satisfaction with ravulizumab treatment for generalized myasthenia gravis in the United States

HTML

Real-world biologics in generalized myasthenia gravis: evidence for reduced hospitalization rates

PDF

The phase 4 OCTAGON study investigating oral corticosteroid tapering in adult patients with generalized myasthenia gravis (gMG) treated with ravulizumab: trial in progress

HTML

Validation of ME&MG(TM) digital biomarkers in monitoring generalized myasthenia gravis symptoms: the DOMYA study

PDF

Adult patients' experiences with selumetinib treatment versus placebo for neurofibromatosis type 1-plexiform neurofibroma associated symptoms and their impacts: a qualitative sub-study of a phase 3, placebo-controlled trial (KOMET)

PDF

Effect of selumetinib treatment on long-term prescription pain medication utilization in adults: a retrospective study of a us claims database

HTML

A real-world study of the effectiveness and safety of ravulizumab in AQP4-Ab+ NMOSD patients with suboptimal response to satralizumab in Japan - interim analysis

HTML

Clinical and radiological outcomes in people with aquaporin-4 antibody positive neuromyelitis optica spectrum disorder following ravulizumab treatment (AMAZE)

PDF

Financial and mental health burden on caregivers of patients with neuromyelitis optica spectrum disorder (NMOSD) in the United States

PDF

Gene expression signatures associated with prior rituximab treatment in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder in the CHAMPION-NMOSD trial

PDF

Long-term efficacy and safety of ravulizumab in anti-aquaporin-4 antibody-positive (aqp4 ab+) neuromyelitis optica spectrum disorder (NMOSD): final analysis of the phase 3 CHAMPION-NMOSD trial

PDF

Quantifying the lifetime health and societal benefits from earlier diagnosis and access to approved targeted immunotherapies in anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) in the United States

PDF

Real-world clinical outcomes with eculizumab and ravulizumab in anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD): results from the global NMO SPOTLIGHT Registry

HTML

The predictive value of billing codes and treatment data to identify relapse hospitalizations among patients with neuromyelitis optica spectrum disorder (NMOSD)

PDF

Concomitant immunosuppressive therapy use with ravulizumab: analysis of the global MG SPOTLIGHT registry

PDF

Efficacy and safety of subcutaneous self-administered gefurulimab in gMG: primary results from the phase 3, randomized, double-blind, placebo controlled PREVAIL trial

PDF

Impact on healthcare resource utilization in early initiators of ravulizumab versus efgartigimod for treatment of generalized myasthenia gravis in the USA

HTML

ME&MG TM digital biomarkers correlate with equivalent MG-ADL and MG-QoL15r sub-items scores

PDF

MG-ADL subdomain score changes with eculizumab or ravulizumab: an analysis of the global MG SPOTLIGHT registry

PDF

Patient satisfaction with ravulizumab treatment for generalized myasthenia gravis in the United States

HTML

Real-world biologics in generalized myasthenia gravis: evidence for reduced hospitalization rates

PDF

The phase 4 OCTAGON study investigating oral corticosteroid tapering in adult patients with generalized myasthenia gravis (gMG) treated with ravulizumab: trial in progress

HTML

Validation of ME&MG(TM) digital biomarkers in monitoring generalized myasthenia gravis symptoms: the DOMYA study

PDF

Adult patients' experiences with selumetinib treatment versus placebo for neurofibromatosis type 1-plexiform neurofibroma associated symptoms and their impacts: a qualitative sub-study of a phase 3, placebo-controlled trial (KOMET)

PDF

Effect of selumetinib treatment on long-term prescription pain medication utilization in adults: a retrospective study of a us claims database

HTML

A real-world study of the effectiveness and safety of ravulizumab in AQP4-Ab+ NMOSD patients with suboptimal response to satralizumab in Japan - interim analysis

HTML

Clinical and radiological outcomes in people with aquaporin-4 antibody positive neuromyelitis optica spectrum disorder following ravulizumab treatment (AMAZE)

PDF

Financial and mental health burden on caregivers of patients with neuromyelitis optica spectrum disorder (NMOSD) in the United States

PDF

Gene expression signatures associated with prior rituximab treatment in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder in the CHAMPION-NMOSD trial

PDF

Long-term efficacy and safety of ravulizumab in anti-aquaporin-4 antibody-positive (aqp4 ab+) neuromyelitis optica spectrum disorder (NMOSD): final analysis of the phase 3 CHAMPION-NMOSD trial

PDF

Quantifying the lifetime health and societal benefits from earlier diagnosis and access to approved targeted immunotherapies in anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) in the United States

PDF

Real-world clinical outcomes with eculizumab and ravulizumab in anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD): results from the global NMO SPOTLIGHT Registry

HTML

The predictive value of billing codes and treatment data to identify relapse hospitalizations among patients with neuromyelitis optica spectrum disorder (NMOSD)

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States